Nature Cell Biology Impact Factor

The 19.1 JIF places Nature Cell Biology firmly in the top tier of cell biology, ranking 10th out of 204 journals. The five-year JIF (22.6) running well above the two-year figure tells you papers here keep accumulating citations long after publication. That's the profile of a journal publishing work that becomes reference material for the cell biology community.

Nature Cell Biology publishes about 205 citable items per year. That's relatively low volume, meaning the journal is genuinely selective. The total citation count (47,872) reflects the community's reliance on its content, and individual papers get strong editorial promotion through the Nature Portfolio platform.

At 19.1, Nature Cell Biology sits between the broader Nature Portfolio flagships (Nature itself, Nature Medicine) and the mid-tier Nature Research journals. It competes directly with Molecular Cell (16.6) and Developmental Cell (8.7) within the cell biology space, and it outperforms EMBO Journal (8.3) significantly.

Nature Cell Biology has been relatively stable in the 17-21 range, with a 2021 pandemic-era spike. The current 19.1 is within the journal's historical range.

• whether the cell biology in your paper is broad enough for a Nature-branded journal
• how Nature Portfolio's editorial process compares to Cell Press for your specific topic
• how long the review and revision cycle will take (often substantial)
• whether the paper should aim higher at Nature or Science
• how your specific paper will perform relative to the journal average

For cell biologists with a strong paper, the Nature Cell Biology vs. Molecular Cell decision is often the central strategic choice. Here's how to think about it:

Nature Cell Biology wants cell biology with broad field relevance. The paper should advance understanding of a cell biological process in a way that matters to the wider community. Nature Portfolio values clear narrative, strong figures, and work that can be appreciated by readers beyond the immediate subfield.

Molecular Cell wants mechanistic depth. The paper should resolve a molecular mechanism with multiple lines of evidence. Cell Press values experimental thoroughness and the mechanistic resolution of the story, even if the broader conceptual reach is more focused.

If your paper's strength is broad cell biology significance with clear visual data, Nature Cell Biology is often the better target. If the strength is deep mechanistic resolution of a molecular process, Molecular Cell may be more natural. And if the work truly transcends cell biology into broader biological significance, Nature itself might be the right first target.

In our pre-submission review work with cell biology manuscripts, Nature Cell Biology has three editorial patterns that separate desk rejections from papers that reach review:

Molecular Cell territory submitted as Nature Cell Biology. The most frequent misalignment we see: deeply mechanistic molecular biology papers where the primary contribution is a resolved protein-protein interaction, a structural mechanism, or an in vitro biochemical reconstitution. Nature Cell Biology wants papers where the central question is about cell behavior, organization, or function, not papers where a molecular machine's mechanism is the achievement in itself. If the main figures are biochemical assays, structural data, or in vitro reconstitution experiments without cellular consequence as the primary finding, the paper reads more naturally to Molecular Cell reviewers. Nature Cell Biology editors can tell when a paper has been submitted here primarily for the Nature brand rather than because of genuine editorial fit.

Disease framing that obscures the cell biology. Nature Cell Biology wants the cell biology to be the scientific contribution. Papers that lead with disease significance (cancer progression, neurodegeneration, metabolic dysfunction) and present the cell biology as mechanistic support for a disease finding are often better suited for Nature Medicine, Nature Metabolism, or disease-focused journals. The tell is a paper where the introduction is organized around a disease problem and the cell biology is framed as "how this disease develops" rather than "what this reveals about cell biology." Editors notice when the disease is doing the persuasive work and the cell biology is secondary. The cell biology must be the discovery, not the explanation.

Imaging-only papers that skip the biological interpretation. Nature Cell Biology has a strong tradition in quantitative cell biological imaging, it's one of the few journals where exceptional microscopy data genuinely moves the editorial needle. But "exceptional imaging" is not sufficient on its own. We see well-executed single-cell tracking papers, organelle dynamics studies, and live-cell imaging experiments that describe cell behavior in impressive detail without making a compelling argument about what that behavior means biologically. Beautiful data without functional mechanistic follow-up tends to return with requests for rescue experiments, genetic validation, or biochemical data that addresses the "why" behind the imaging observation.

Nature Cell Biology editors want:

• mechanistic cell biology with broad relevance to the field
• strong visual and quantitative data (microscopy, quantitative imaging)
• work that advances understanding of fundamental cell processes
• papers on cell division, signaling, metabolism, migration, or fate decisions
• clear narrative that a broad cell biology readership can follow

The journal has grown its coverage of cell metabolism, mechanotransduction, and organelle biology in recent years. Papers that connect cell biology to disease (especially cancer cell biology) have a strong track record, provided the cell biology is the central contribution rather than the disease angle.

Submit if:

• the paper advances cell biology understanding with real mechanistic depth
• the work matters beyond one narrow subfield of cell biology
• the manuscript meets Nature Portfolio quality standards for figures and narrative
• you want Nature branding in the cell biology space

Think twice if:

• Cell is a realistic target and the story has broader conceptual reach
• Molecular Cell would better serve a deeply mechanistic, focused story
• the cell biology angle is secondary to a disease or developmental biology finding
• EMBO Journal is a more natural editorial home for the topic

Nature Cell Biology at 19.1 is best understood as a high-trust specialty flagship with Nature Portfolio branding, not as a generic middle point between Cell and Molecular Cell. The citation trend supports that reading. The journal stayed in a strong band after the pandemic-era distortions settled, which tells authors the current number still reflects durable influence within cell biology rather than a temporary boost.

That matters because cell-biologists often misread the decision as a simple prestige ladder. Nature Cell Biology does not mainly reward the same thing as Molecular Cell. It usually favors papers that make a broad cell-biology argument clearly and visually, often with strong imaging, quantitative analysis, and a narrative that travels beyond one mechanistic corner. If the paper's strength is deep molecular resolution more than broad cell-biological framing, the impact factor alone can point you toward the wrong venue.

The trend is useful because it keeps the strategy honest. Nature Cell Biology remains strong enough that the relevant question is not whether 19.1 is high. It is whether the manuscript reads like a paper the broader cell-biology community would actually pass around and teach from.